目的观察川芎嗪与噻氯匹啶联合治疗缺血性脑血管病的临床疗效。方法将 76例病人 ,男 42例 ,女 34例 ,随机分为 3组 ,治疗组 :川芎嗪加噻氯匹啶 32例 ;对照组 1:单用噻氯匹啶 2 0例 ;对照组 2 :单用川芎嗪 2 4例。一月为一个疗程。结果治疗组总有效率 (96 85 % ) ,优于对照组 1及对照组 2 (70 %、87 5 % ) ,一年后复发率 9% ,对照组为 13 6 %和 11 3%。结论川芎嗪加噻氯匹啶治疗缺血性脑血管病优于单用川芎嗪或噻氯匹啶的治疗。 Objective To observe the clinical efficacy of ligustrazine and ticlopidine in the treatment of ischemic cerebrovascular disease. Methods Totally 76 patients, 42 males and 34 females, were randomly divided into 3 groups: treatment group: ligustrazine plus ticlopidine 32 cases; control group 1: ticlopidine alone 20 cases; control group 2 : Twenty four cases of ligustrazine alone. January is a course of treatment. Results The total effective rate (96 85%) in the treatment group was better than that in the control group 1 and the control group 2 (70%, 87 5%). The recurrence rate was 9% after one year and 136% and 113% respectively in the control group. Conclusion Ligustrazine plus ticlopidine is superior to ligustrazine or ticlopidine in the treatment of ischemic cerebrovascular disease.